Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × cediranib × Genitourinary × Clear all

Phase

Status

Sponsor Class

NIH 9 INDUSTRY 2 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 9 Sarcoma 4 Gastrointestinal 3 Thoracic 2 Genitourinary 1 Dermatologic 1 CNS 1 Breast 1

Conditions

Carcinoma, Renal Cell 1

Interventions

Docetaxel 229 Radiotherapy 204 Magnetic Resonance Spectroscopy 201 Radiosurgery 175 Gemcitabine 153 pembrolizumab 150 Nivolumab 146 enzalutamide 139 Prednisone 129 Cisplatin 122 Leuprolide 119 Androgen Antagonists 117 Abiraterone Acetate 114 Sunitinib 106 Specimen Handling 92 Surveys and Questionnaires 91 Goserelin 91 Carboplatin 89 bicalutamide 88 Ipilimumab 82 gallium 68 PSMA-11 80 Blood Specimen Collection 77 apalutamide 73 Everolimus 73 Radiation 71 Standard of Care 68 Biopsy 68 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 66 Paclitaxel 65 Cyclophosphamide 62

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03741426 2023-06-07

WIRE

Cambridge University Hospitals NHS Foundation Trust

Phase 2 Unknown

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡